Merck (MRK) Reports Positive Phase III Data For Suvorexant
Tweet Send to a FriendGet Alerts MRK Hot Sheet
Price: $47.58 -0.36%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 3.6%
Revenue Growth %: -99.9%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 3.6%
Revenue Growth %: -99.9%
Trade MRK Now!
Merck (NYSE: MRK) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia.
In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Other key points: 1) Suvorexant Achieved Statistical Significance on 15 of 16 Primary Endpoints; 2) Merck Remains on Track to File a New Drug Application for Suvorexant in 2012,One of the Six Major Pipeline Filings Merck Plans for 2012 and 2013
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Other key points: 1) Suvorexant Achieved Statistical Significance on 15 of 16 Primary Endpoints; 2) Merck Remains on Track to File a New Drug Application for Suvorexant in 2012,One of the Six Major Pipeline Filings Merck Plans for 2012 and 2013
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck (MRK) to Further Streamline R&D Unit; Job Cuts Planned
- Men's Wearhouse (MW) Terminates George Zimmer; Postpones Annual Meeting
- Amarin (AMRN) Vascepa sNDA Set for Oct. 16, 2013, According to FDA
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
